Year: 2025

WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted on November 4, November 10, and November 17, 2025, and entitle the recipients to purchase 24,000 shares of common stock, 72,000 shares of common stock, and 18,000 shares of common stock, respectively,...

Paris, France – November 17, 2025 – Eviden, the Atos Group product brand leading in advanced computing, announces today the rankings of its 58 Eviden-built systems1 in the TOP500 and Green500, official listings of the world’s most powerful and most energy-efficient supercomputers. Amongst the 58 Eviden-built systems listed in the TOP500, JUPITER, through its Booster partition, remains the 4th most powerful supercomputer in the world and Europe’s 1st, marking a historic milestone as Europe’s first system to officially break the symbolic ExaFlop barrier – one billion billion calculations per second. Eviden also leads the Green500 for the fourth edition in a row, claiming the top three spots with its Eviden-built systems KAIROS (CALMIP), ROMEO (URCA), and the Levante GPU extension (DKRZ) – and with JUPITER being recognized as the most energy-efficient...

MONTREAL, Nov. 17, 2025 (GLOBE NEWSWIRE) — MTY Food Group Inc. (“MTY”, “MTY Group” or the “Company”) (TSX: MTY), one of the largest franchisors and operators of multiple restaurant concepts worldwide, is responding to certain statements in the media. Following a recent press article, MTY Group confirms that the Board of Directors of the Company has initiated a strategic review process and engaged a financial advisor to identify, review and evaluate potential strategic alternatives with a view toward continuing to enhance shareholder value. The Company is exploring a range of such alternatives including, but not limited to, a sale of all or part of the company as well as continuing to execute its current business plan. There can be no assurance that any transaction will occur, and the Company...

WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 451,448 shares of the Company’s ordinary shares to eight non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on November 14, 2025 and were material to each employee’s acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4). The options were granted with a 10-year term and an exercise price...

CHANDLER, Ariz., Nov. 17, 2025 (GLOBE NEWSWIRE) — (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Wells Fargo 9th Annual TMT Summit on Tuesday, November 18, 2025 at 12:45 p.m. (Pacific Time). Presenting for the Company will be Mr. Eric Bjornhoolt, Senior Vice President and Chief Financial Officers, and Mr. Sajid Daudi, Head of Investor Relations. A live webcast of the presentation will be made available by Wells Fargo, and can be accessed on the Microchip website at www.microchip.com. Any forward looking statements made during the presentation are qualified in their entirety by the discussion of risks set forth in the Company’s Securities and Exchange Commission filings. Copies of SEC filings...

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters’ option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec’s total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) are approximately $40,250,000. Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness and the remaining net proceeds for working capital and general corporate purposes. Piper Sandler & Co. and Craig-Hallum Capital Group LLC acted as the...

Hong Kong, Nov. 17, 2025 (GLOBE NEWSWIRE) — Click Holdings Limited (“Click Holdings” or “Click” or “we” or “us”, NASDAQ: CLIK) and its subsidiaries (collectively, the “Company”), Hong Kong’s only Nasdaq-listed leader in human resources and senior care solutions, announced to acquire 100% equity interest in Bowser Human Resources Limited (“Bowser”) and Top Team Consultants Limited (“Top Team”), being two Hong Kong-based human resources solutions providers operating in the region, by the issuance of 1,885,350 and 232,256 Class A ordinary shares of the Company respectively. These acquisitions will supercharge Click’s strategic growth, unlock synergies, and propel the Company to new heights of market dominance by further solidifying our fast-growing talent pools. “These acquisitions affirm our ambition to continue expanding our presence...

WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. Eastern Time. A live webcast and replay of the presentation will be accessible on Clover Health’s investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is...

MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the “Grant Date”). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with...